NASDAQ:SCYX SCYNEXIS (SCYX) Stock Forecast, Price & News $2.28 -0.02 (-0.87%) (As of 09/29/2023 08:53 PM ET) Add Compare Share Share Today's Range$2.25▼$2.4750-Day Range$1.93▼$3.6552-Week Range$1.15▼$3.87Volume354,900 shsAverage Volume839,075 shsMarket Capitalization$84.77 millionP/E Ratio2.71Dividend YieldN/APrice Target$11.40 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media SCYNEXIS MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside400.0% Upside$11.40 Price TargetShort InterestHealthy3.66% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.38Based on 19 Articles This WeekInsider TradingN/AProj. Earnings Growth-91.32%From $2.65 to $0.23 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.20 out of 5 starsMedical Sector426th out of 968 stocksPharmaceutical Preparations Industry185th out of 450 stocks 3.5 Analyst's Opinion Consensus RatingSCYNEXIS has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.40, SCYNEXIS has a forecasted upside of 400.0% from its current price of $2.28.Amount of Analyst CoverageSCYNEXIS has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.66% of the outstanding shares of SCYNEXIS have been sold short.Short Interest Ratio / Days to CoverSCYNEXIS has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in SCYNEXIS has recently increased by 2.26%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldSCYNEXIS does not currently pay a dividend.Dividend GrowthSCYNEXIS does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SCYX. Previous Next 3.0 News and Social Media Coverage News SentimentSCYNEXIS has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for SCYNEXIS this week, compared to 1 article on an average week.Search Interest10 people have searched for SCYX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows14 people have added SCYNEXIS to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SCYNEXIS insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.40% of the stock of SCYNEXIS is held by insiders.Percentage Held by Institutions49.87% of the stock of SCYNEXIS is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for SCYNEXIS are expected to decrease by -91.32% in the coming year, from $2.65 to $0.23 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SCYNEXIS is 2.71, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 110.66.Price to Earnings Ratio vs. SectorThe P/E ratio of SCYNEXIS is 2.71, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 101.16.Price to Book Value per Share RatioSCYNEXIS has a P/B Ratio of 22.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About SCYNEXIS (NASDAQ:SCYX) StockSCYNEXIS, Inc., a biotechnology company, develops products for the treatment of fungal infections in the United States. It offers BREXAFEMME for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of various fungal infections, including invasive candidiasis, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.Read More SCYX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SCYX Stock News HeadlinesSeptember 29, 2023 | tmcnet.comKirby McInerney LLP Announces Investigation of Shareholder Claims Against Scynexis, Inc. (SCYX)September 28, 2023 | businesswire.comSCYNEXIS ALERT: Bragar Eagel & Squire, P.C. is Investigating SCYNEXIS, Inc. on Behalf of Scynexis Stockholders and Encourages Investors to Contact the FirmOctober 2, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.September 28, 2023 | tmcnet.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Scynexis, Inc. (SCYX) on Behalf of InvestorsSeptember 28, 2023 | barrons.comSCYNEXIS, Inc. (SCYX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsSeptember 27, 2023 | stockhouse.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SCYNEXIS, Inc. - SCYXSeptember 27, 2023 | benzinga.comThe Law Offices of Frank R. Cruz Continues Investigation of Scynexis, Inc. (SCYX) on Behalf of InvestorsSeptember 26, 2023 | msn.comScynexis: From Fungal To Bungle, The Brexafemme Recall And A Slippery Slope (Rating Downgrade)October 2, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.September 26, 2023 | markets.businessinsider.comScynexis Recalls GSK- Licensed Ibrexafungerp Tablets, Halts Trials On Contamination ConcernsSeptember 26, 2023 | americanbankingnews.comHead-To-Head Review: SCYNEXIS (NASDAQ:SCYX) & Alkermes (NASDAQ:ALKS)September 25, 2023 | benzinga.comINVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Scynexis, Inc. (SCYX) on Behalf of InvestorsSeptember 25, 2023 | markets.businessinsider.comNasdaq Turns Higher; SCYNEXIS Shares PlungeSeptember 25, 2023 | tmcnet.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Scynexis, Inc. (SCYX) on Behalf of InvestorsSeptember 25, 2023 | benzinga.comThe Law Offices of Frank R. Cruz Announces Investigation of Scynexis, Inc. (SCYX) on Behalf of InvestorsSeptember 25, 2023 | msn.comWhy Are Antifungal Focused Scynexis Stock Plunging Today?September 25, 2023 | marketwatch.comScynexis Shares Fall More Than 30% After Brexafemme Recall >SCYXSeptember 25, 2023 | reuters.comScynexis to recall antifungal from market, pause studiesSeptember 25, 2023 | marketwatch.comScynexis Shares Slide Premarket on Brexafemme Recall, Study Hold >SCYXSeptember 12, 2023 | finance.yahoo.comSCYNEXIS, Inc.'s (NASDAQ:SCYX) Stock Is Going Strong: Have Financials A Role To Play?September 4, 2023 | finance.yahoo.comSCYNEXIS (SCYX) Skyrockets 134% Year to Date: Here's WhyAugust 28, 2023 | finance.yahoo.comSCYNEXIS to Participate in September Investor ConferencesAugust 16, 2023 | markets.businessinsider.comSCYNEXIS (SCYX) Receives a Buy from Maxim GroupAugust 16, 2023 | finance.yahoo.comLittle Excitement Around SCYNEXIS, Inc.'s (NASDAQ:SCYX) RevenuesAugust 15, 2023 | finanznachrichten.deScynexis: SCYNEXIS Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 15, 2023 | msn.comCantor Fitzgerald Reiterates Scynexis (SCYX) Overweight RecommendationAugust 14, 2023 | seekingalpha.comSCYNEXIS GAAP EPS of $2.46 beats by $1.01, revenue of $131.5M beats by $36.1MSee More Headlines Receive SCYX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SCYNEXIS and its competitors with MarketBeat's FREE daily newsletter. Email Address SCYX Company Calendar Last Earnings8/14/2023Today10/02/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SCYX CUSIPN/A CIK1178253 Webwww.scynexis.com Phone(201) 884-5485Fax201-884-5490Employees36Year FoundedN/APrice Target and Rating Average Stock Price Forecast$11.40 High Stock Price Forecast$15.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+400.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$0.84 Trailing P/E Ratio2.71 Forward P/E Ratio0.86 P/E GrowthN/ANet Income$-62,810,000.00 Net Margins32.71% Pretax Margin32.71% Return on Equity317.92% Return on Assets62.50% Debt Debt-to-Equity Ratio0.12 Current Ratio9.01 Quick Ratio8.37 Sales & Book Value Annual Sales$5.09 million Price / Sales16.65 Cash FlowN/A Price / Cash FlowN/A Book Value$0.10 per share Price / Book22.80Miscellaneous Outstanding Shares37,180,000Free Float35,540,000Market Cap$84.77 million OptionableOptionable Beta2.14 The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. David Gonzalez Angulo M.D. (Age 58)CEO, Pres & Director Comp: $631.69kMr. Scott Sukenick J.D. (Age 45)Chief Legal Officer & Corp. Sec. Comp: $542.05kMr. Ivor Macleod CPA (Age 62)M.B.A., Chief Financial Officer Debbie EtchisonExec. Director of CommunicationsMs. Daniella GiganteVP of HR & Information TechnologyKey CompetitorsCorvus PharmaceuticalsNASDAQ:CRVSVeruNASDAQ:VERUEliem TherapeuticsNASDAQ:ELYMHCW BiologicsNASDAQ:HCWBIncannex HealthcareNASDAQ:IXHLView All CompetitorsInstitutional OwnershipStonepine Capital Management LLCBought 2,496,346 shares on 8/16/2023Ownership: 8.068%Walleye Capital LLCBought 225,653 shares on 8/15/2023Ownership: 0.645%Goldman Sachs Group Inc.Bought 20,566 shares on 8/15/2023Ownership: 0.056%Corsair Capital Management L.P.Bought 18,000 shares on 8/15/2023Ownership: 0.049%Citadel Advisors LLCSold 27,000 shares on 8/15/2023Ownership: 0.000%View All Institutional Transactions SCYX Stock - Frequently Asked Questions Should I buy or sell SCYNEXIS stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SCYNEXIS in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SCYX shares. View SCYX analyst ratings or view top-rated stocks. What is SCYNEXIS's stock price forecast for 2023? 4 brokers have issued 1-year target prices for SCYNEXIS's shares. Their SCYX share price forecasts range from $8.00 to $15.00. On average, they predict the company's stock price to reach $11.40 in the next year. This suggests a possible upside of 400.0% from the stock's current price. View analysts price targets for SCYX or view top-rated stocks among Wall Street analysts. How have SCYX shares performed in 2023? SCYNEXIS's stock was trading at $1.56 on January 1st, 2023. Since then, SCYX shares have increased by 46.2% and is now trading at $2.28. View the best growth stocks for 2023 here. When is SCYNEXIS's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our SCYX earnings forecast. How were SCYNEXIS's earnings last quarter? SCYNEXIS, Inc. (NASDAQ:SCYX) issued its quarterly earnings data on Monday, August, 14th. The company reported $2.46 EPS for the quarter, topping analysts' consensus estimates of $1.03 by $1.43. The business earned $131.45 million during the quarter, compared to the consensus estimate of $91.50 million. SCYNEXIS had a trailing twelve-month return on equity of 317.92% and a net margin of 32.71%. When did SCYNEXIS's stock split? SCYNEXIS's stock reverse split before market open on Friday, July 17th 2020. The 1-10 reverse split was announced on Thursday, July 16th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 16th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of SCYNEXIS own? Based on aggregate information from My MarketBeat watchlists, some companies that other SCYNEXIS investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Sorrento Therapeutics (SRNE), Gran Tierra Energy (GTE), KushCo (KSHB), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), Outlook Therapeutics (OTLK), Cogent Biosciences (UMRX) and Aeterna Zentaris (AEZS). What is SCYNEXIS's stock symbol? SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX." How do I buy shares of SCYNEXIS? Shares of SCYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is SCYNEXIS's stock price today? One share of SCYX stock can currently be purchased for approximately $2.28. How much money does SCYNEXIS make? SCYNEXIS (NASDAQ:SCYX) has a market capitalization of $84.77 million and generates $5.09 million in revenue each year. The company earns $-62,810,000.00 in net income (profit) each year or $0.84 on an earnings per share basis. How can I contact SCYNEXIS? SCYNEXIS's mailing address is 1 EVERTRUST PLAZA 13TH FLOOR, JERSEY CITY NJ, 07302. The official website for the company is www.scynexis.com. The company can be reached via phone at (201) 884-5485, via email at ikoffler@lifesciadvisors.com, or via fax at 201-884-5490. This page (NASDAQ:SCYX) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SCYNEXIS, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.